Volume 10,Issue 4
Analysis of the Effects of Different Medication Methods on the Acute Attack Rate, Pulmonary Function, and Safety of Prophylactic Treatment in Patients with Seasonal Asthma
Objective: To investigate the effects of different medication methods on the acute attack rate, pulmonary function, and safety of prophylactic treatment in patients with seasonal asthma. Methods: A total of 180 outpatient asthma patients with seasonal attack characteristics, admitted to our hospital from March 2022 to September 2025, were selected as the study subjects. They were randomly divided into two groups using the random number table method. Patients in the budesonide group inhaled budesonide-formoterol powder inhalation, while those in the montelukast group took oral montelukast sodium tablets. The acute attack rate, pulmonary function indicators, and medication safety were compared between the two groups. Results: The acute attack rate in the budesonide group (6.67%) was lower than that in the montelukast group (16.67%), with a statistically significant difference between the two groups (P<0.05). Before treatment, there were no significant differences in pulmonary function indicators such as FEV1% predicted, FEV1/FVC%, and PEF between the two groups (P>0.05). After treatment, both groups showed significant improvements in pulmonary function indicators, with the budesonide group significantly outperforming the montelukast group (P<0.05). During the treatment period, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: In the prophylactic treatment of seasonal asthma, the combined budesonide-formoterol inhalation regimen is superior to montelukast sodium in preventing acute attacks and improving pulmonary function, with comparable safety, and can be considered as the preferred prophylactic treatment option in clinical practice.
[1] Papadopoulos NG, Miligkos M, Xepapadaki P, 2022, A Current Perspective of Allergic Asthma: From Mechanisms to Management. Handb Exp Pharmacol, 268: 69-93.
[2] Nappi E, Paoletti G, Malvezzi L, et al., 2022, Comorbid allergic rhinitis and asthma: important clinical considerations. Expert Rev Clin Immunol, 18(7): 747-758.
[3] Oppenheimer J, Hoyte FCL, Phipatanakul W, et al., 2022, Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma Immunol, 129(2): 169-180.
[4] Gans MD, Gavrilova T, 2020, Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes. Paediatr Respir Rev, 36: 118-127.
[5] Garagorri-Gutiérrez D, Leirós-Rodríguez R, 2022, Effects of physiotherapy treatment in patients with bronchial asthma: A systematic review. Physiother Theory Pract, 38(4): 493-503.
[6] Papi A, Chipps BE, Beasley R, et al., 2022, Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. N Engl J Med, 386(22): 2071-2083.
[7] Beasley R, Harrison T, Peterson S, et al., 2022, Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis. JAMA Netw Open, 5(3): e220615.
[8] Papi A, Ferreira DS, Agache I, et al., 2023, European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma. Eur Respir J, 62(4): 2300047.
[9] Mayoral K, Lizano-Barrantes C, Zamora V, et al., 2023, Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis. Eur Respir Rev, 32(170): 230124.
[10] Chinese Thoracic Society, Chinese Medical Association, 2025, Guidelines for the prevention and management of bronchial asthma (2024 edition). Zhonghua Jie He He Hu Xi Za Zhi, 48(3): 208-248.
[11] Breiteneder H, Peng YQ, Agache I, et al., 2020, Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy, 75(12): 3039-3068.
[12] Jung M, Lee JY, Ryu G, et al., 2020, Beneficial effect of nasal saline irrigation in children with allergic rhinitis and asthma: A randomized clinical trial. Asian Pac J Allergy Immunol, 38(4): 251-257.
[13] Chen F, Liang L, Chu FF, et al., 2023, Effects of omalizumab combined with budesonide formoterol on clinical efficacy, pulmonary function, immune function, and adverse reactions in children with moderate and severe allergic asthma. Allergol Immunopathol (Madr), 51(4): 182-188.
[14] Xu QY, Li LS, Xu YY, et al., 2025, A case report of delayed drug hypersensitivity reaction caused by inhalation and nasal spray of budesonide. Zhonghua Jie He He Hu Xi Za Zhi, 48(9): 848-852.
[15] Shao M, Sun J, Zheng Q, 2025, Efficacy and safety of montelukast-levocetirizine combination therapy in combined allergic rhinitis and asthma syndrome: a systematic review and meta-analysis. J Asthma, 62(3): 376-385.
[16] Ortiz M, de Sa Coutinho D, Ciambarella BT, et al., 2020, Intranasal administration of budesonide-loaded nanocapsule microagglomerates as an innovative strategy for asthma treatment. Drug Deliv Transl Res, 10(6): 1700-1715.
[17] Ozseker ZF, Aksu K, Mutlu LC, et al., 2022, Expert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction-Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS/LABA. Curr Allergy Asthma Rep, 22(10): 123-134.